Navigation Links
One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Date:5/15/2012

same platinum chromium alloy and similar design used in the PROMUS Element Stent with a novel coating created to significantly reduce the amount of polymer and drug to which the blood vessel wall is exposed, without compromising inhibition of neointimal growth," said Keith D. Dawkins, M.D., global chief medical officer for Boston Scientific.  "SYNERGY is designed to address potential limitations with durable polymer coatings used on currently available drug-eluting stents, including issues with dual antiplatelet therapy interruption and duration. We continue to be pleased with the impressive clinical and angiographic results from the EVOLVE trial for this advanced coronary stent technology."

EVOLVE trial data are expected to support CE Mark approval for the SYNERGY Stent, which is expected as early as later this year, while additional larger studies are anticipated to further assess clinical event rates and the potential for reduced dual antiplatelet therapy with this novel stent technology. 

The SYNERGY Stent is an investigational device, limited by applicable law to investigational use only and not available for sale. 

About the SYNERGY Stent

The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug combination to create an ultra-thin, uniform coating applied to the outer (abluminal) surface of the stent.  After the drug has been delivered, the bioabsorbable coating is designed to absorb within four months of implantation, leaving only a bare-metal PtCr stent.  This technology is designed to provide the same degree of restenosis reduction as a conventional drug-eluting stent while offering faster and more complete vessel healing after stent implantation, which could potentially reduce the duration or allow safer interruption of post-procedure dual antiplatelet therapy.  The SYNERGY Stent features the same proprietary platinum chromium alloy and similar stent design used in the PROMUS
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohns Disease
6. Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
9. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Elekta VMAT Radiation Therapy Rapidly Gaining Users Worldwide as Technique Evolves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... 1 Clinicians at Institut Catala d,Oncologia (ICO) in Barcelona ... RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate cancer ... country to receive the fast and efficient treatment. , ... "The treatment went very well and the patient ...
... SAN DIEGO , June 1, 2010 Amylin Pharmaceuticals, ... , MD has been appointed Senior Vice President, Research and Development. ... Chief Medical Officer. These leadership changes will strengthen the Company,s focus ... its late-stage development programs, both important value drivers for the Company. ...
Cached Medicine Technology:Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 2Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 3Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 5
(Date:9/2/2014)... September 02, 2014 Eric Jimenez and ... Me , a revolutionary makeup application device. Designed to ... proven innovation in the palm of women’s hands to ... secret to Color Me’s success lies in its patented ... a rate of 15,000 pulses per minute, the device ...
(Date:9/2/2014)... NJ (PRWEB) September 02, 2014 BESLER ... protection services for hospitals, is pleased to announce that ... in-depth review of the FY 2015 Hospital Inpatient ... the Centers for Medicare & Medicaid Services. , “Hospitals ... variety of reasons,” said Jonathan Besler, BESLER’s President and ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the world-famous ... Lee has the unique distinction of being the first and ... history, Misty Lee is the first female magician to hold ... staff Medium at the Magic Castle,” says Misty Lee. “Even ... being at the Magic Castle, I can fascinate guests in ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
Breaking Medicine News(10 mins):Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5
... who fear their own death say they are more prepared ... whom further medical treatment is considered futile,// reveals research published ... Archives of Disease in Childhood. ,The findings ... in the care of sick newborns (neonatologists) across Australia and ...
... low numbers of organ donors in Australia is an ongoing ... ,In the latest edition of the Medical Journal ... of the issues surrounding organ donation in Australia. ... the second the impact of public education campaigns on organ ...
... According to a latest Government data, there is an alarming ... this could be linked to the plummeting sale of// antidepressants. ... and Prevention (CDC) also indicated that youth in their late ... Food and Drug Administration had issued a black box warning ...
... using a sophisticated form of analysis called meta-analysis, in which ... for// possibly preventing up to half of the cases of ... in the United States. The work was conducted by a ... Center at University of California, San Diego (UCSD), and colleagues ...
... the United States and a growing epidemic worldwide. Now, ... able to make a valuable contribution to an overall ... ,A study published in the Journal of Vertebral ... when used as part of an integrative treatment in ...
... there is a pronounced increase of mental illnesses ... spectrum disorders, obsessive// compulsive disorders and hyperkinetic illnesses. ... Pediatric and Adolescent Medicine. ,Researches are ... to the increased awareness about these diseases or ...
Cached Medicine News:Health News:Doctors’ Own Fear of Death Linked to Hastening Death of Very Sick Newborn 2Health News:The Search for Organ Donors 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Research Explores Chiropractic's Effect on Diabetes 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: